BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 24578176)

  • 41. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group.
    Anglian Breast Cancer Study Group
    Br J Cancer; 2000 Nov; 83(10):1301-8. PubMed ID: 11044354
    [TBL] [Abstract][Full Text] [Related]  

  • 42. BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.
    Capalbo C; Ricevuto E; Vestri A; Ristori E; Sidoni T; Buffone O; Adamo B; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
    Ann Oncol; 2006 Jun; 17 Suppl 7():vii34-40. PubMed ID: 16760289
    [TBL] [Abstract][Full Text] [Related]  

  • 43. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mammographic density and breast cancer in women from high risk families.
    Ramón Y Cajal T; Chirivella I; Miranda J; Teule A; Izquierdo Á; Balmaña J; Sánchez-Heras AB; Llort G; Fisas D; Lope V; Hernández-Agudo E; Juan-Fita MJ; Tena I; Robles L; Guillén-Ponce C; Pérez-Segura P; Luque-Molina MS; Hernando-Polo S; Salinas M; Brunet J; Salas-Trejo MD; Barnadas A; Pollán M
    Breast Cancer Res; 2015 Jul; 17(1):93. PubMed ID: 26163143
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inherited mutations in
    Wen WX; Allen J; Lai KN; Mariapun S; Hasan SN; Ng PS; Lee DS; Lee SY; Yoon SY; Lim J; Lau SY; Decker B; Pooley K; Dorling L; Luccarini C; Baynes C; Conroy DM; Harrington P; Simard J; Yip CH; Mohd Taib NA; Ho WK; Antoniou AC; Dunning AM; Easton DF; Teo SH
    J Med Genet; 2018 Feb; 55(2):97-103. PubMed ID: 28993434
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High prevalence of BRCA1 founder mutations in Greek breast/ovarian families.
    Konstantopoulou I; Tsitlaidou M; Fostira F; Pertesi M; Stavropoulou AV; Triantafyllidou O; Tsotra E; Tsiftsoglou AP; Tsionou C; Droufakou S; Dimitrakakis C; Fountzilas G; Yannoukakos D
    Clin Genet; 2014 Jan; 85(1):36-42. PubMed ID: 24010542
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: the Korean Hereditary Breast Cancer (KOHBRA) Study.
    Son BH; Ahn SH; Kim SW; Kang E; Park SK; Lee MH; Noh WC; Kim LS; Jung Y; Kim KS; Noh DY; Moon BI; Suh YJ; Lee JE; Choi DH; Kim SY; Jung SH; Yom CK; Lee H; Yang JH;
    Breast Cancer Res Treat; 2012 Jun; 133(3):1143-52. PubMed ID: 22382806
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Difference in Risk of Breast and Ovarian Cancer According to Putative Functional Domain Regions in Korean BRCA1/2 Mutation Carriers.
    Park JS; Lee ST; Han JW; Kim TI; Nam EJ; Park HS
    Clin Breast Cancer; 2018 Oct; 18(5):362-373.e1. PubMed ID: 29673794
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discoveries beyond BRCA1/2: Multigene testing in an Asian multi-ethnic cohort suspected of hereditary breast cancer syndrome in the real world.
    Ow SGW; Ong PY; Lee SC
    PLoS One; 2019; 14(3):e0213746. PubMed ID: 30875412
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
    Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
    Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
    Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations.
    Yao L; Sun J; Zhang J; He Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Breast Cancer Res Treat; 2016 Apr; 156(3):441-445. PubMed ID: 27033093
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3,922 Korean patients with breast and ovarian cancer.
    Kim H; Cho DY; Choi DH; Choi SY; Shin I; Park W; Huh SJ; Han SH; Lee MH; Ahn SH; Son BH; Kim SW; ; Haffty BG
    Breast Cancer Res Treat; 2012 Aug; 134(3):1315-26. PubMed ID: 22798144
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel.
    Moran O; Nikitina D; Royer R; Poll A; Metcalfe K; Narod SA; Akbari MR; Kotsopoulos J
    Breast Cancer Res Treat; 2017 Jan; 161(1):135-142. PubMed ID: 27798748
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study.
    de Sanjosé S; Léoné M; Bérez V; Izquierdo A; Font R; Brunet JM; Louat T; Vilardell L; Borras J; Viladiu P; Bosch FX; Lenoir GM; Sinilnikova OM
    Int J Cancer; 2003 Sep; 106(4):588-593. PubMed ID: 12845657
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
    Loman N; Johannsson O; Kristoffersson U; Olsson H; Borg A
    J Natl Cancer Inst; 2001 Aug; 93(16):1215-23. PubMed ID: 11504767
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of the need for routine clinical testing of PALB2 c.1592delT mutation in BRCA negative Northern Finnish breast cancer families.
    Haanpää M; Pylkäs K; Moilanen JS; Winqvist R
    BMC Med Genet; 2013 Aug; 14():82. PubMed ID: 23941127
    [TBL] [Abstract][Full Text] [Related]  

  • 58. BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer.
    Shi T; Wang P; Xie C; Yin S; Shi D; Wei C; Tang W; Jiang R; Cheng X; Wei Q; Wang Q; Zang R
    Int J Cancer; 2017 May; 140(9):2051-2059. PubMed ID: 28176296
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
    Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
    Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparing the frequency of common genetic variants and haplotypes between carriers and non-carriers of BRCA1 and BRCA2 deleterious mutations in Australian women diagnosed with breast cancer before 40 years of age.
    Turkovic L; Gurrin LC; Bahlo M; Dite GS; Southey MC; Hopper JL
    BMC Cancer; 2010 Sep; 10():466. PubMed ID: 20807450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.